Ilkovitch, Dan <br/><br/>
MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  Jun 2004 
 - 525-32 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0340-7004 
<br/><br/><label>Standard No.: </label>10.1007/s00262-003-0486-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antigen Presentation<br/>Antigens, Differentiation, B-Lymphocyte--immunology<br/>B7-1 Antigen--genetics<br/>CD4-Positive T-Lymphocytes--immunology<br/>Cancer Vaccines--immunology<br/>Chickens<br/>Egg White<br/>Female<br/>Genes, MHC Class II--genetics<br/>Histocompatibility Antigens Class II--immunology<br/>Interferon-gamma--metabolism<br/>Interleukin-2--metabolism<br/>Interleukin-4--metabolism<br/>Lymphocyte Activation<br/>Mice<br/>Mice, Inbred C3H<br/>Mice, Inbred CBA<br/>Mice, Transgenic<br/>Muramidase--administration & dosage<br/>Sarcoma, Experimental--immunology<br/>Transgenes